The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 26, 2024

Filed:

Feb. 16, 2024
Applicant:

Slayback Pharma Llc, Princeton, NJ (US);

Inventors:

Rahul Dhulaji Bhise, Hyderabad, IN;

Ajay Kumar Singh, Princeton, NJ (US);

Mahadeo Vasant Mahadik, Hyderabad, IN;

Ashish Anilrao Dubewar, Hyderabad, IN;

Molugu Prashanth Reddy, Hyderabad, IN;

Assignee:

SLAYBACK PHARMA LLC, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/27 (2006.01); A61K 31/40 (2006.01); A61K 47/18 (2017.01);
U.S. Cl.
CPC ...
A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/27 (2013.01); A61K 31/40 (2013.01); A61K 47/183 (2013.01);
Abstract

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.


Find Patent Forward Citations

Loading…